Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients

In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept at playing catch-up with Novo Nordisk. | In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept at playing catch-up with Novo Nordisk. On Friday, Lilly checked another item off that list as it secured FDA approval for Mounjaro to reduce the risk of heart attack or stroke in at-risk adults with type 2 diabetes.